Bristol-Myers To Pay Up To $600M For Autoimmune Biotech
New York-based Bristol-Myers Squibb said Wednesday it will pay up to $600 million to nab autoimmune biotech Padlock Therapeutics, marking the pharmaceutical company's latest acquisition as it continues to build out...To view the full article, register now.
Already a subscriber? Click here to view full article